SK Biopharmaceuticals Co., Ltd. reported consolidated earnings results for the first quarter of 2021. The company reported revenue based on consolidated financial statements reached KRW 140 billion, an increase of 770% quarter-on- quarter, including milestone sales of KRW 124.5 billion. The company recorded operating profit of KRW 75.9 billion, turning a profit quarter-on- quarter.